Sample Distribution, Processing, Banking and Database

样品和分子核心（核心B）具有以下功能： 1.建立和维护血液和骨髓标本库，包括完整细胞、血清， 细胞DNA、RNA和蛋白质，来自在M.D.接受治疗或评估的MDS患者。安德森 癌症中心 2.将MDS患者和正常“对照”样本分发给MDS P01研究者。 3.维护一个全面的、前瞻性的、交互式的样本数据库，显示类型（诊断时， AML进展等）和可用MDS样品的特征（DNA、RNA等）以及它们的 后续处置。 4.通过共享血液和骨髓资源促进MDS P01内和外的合作。 5.确定诊断时患者中NRAS、KRAS 2和PTPN 11突变的发生率， 此后每3个月。 6.评估PTPN11、RAS和FLT3突变可用于定量 MDS的疾病负担。 7.测量靶向治疗剂（特别是R115777）的生化终点，并将其与 这些药效学数据与项目1中给予的治疗反应。

The Sample and Molecular Core (Core B) has the following functions: 1. Develop and maintain a repository of blood and bone marrow specimens, including intact cells, serum, cellular DMA, RNA, and protein, from patients with MDS receiving care or evaluation at M.D. Anderson Cancer Center. 2. Distribute samples from MDS patients and normal "controls" to MDS P01 investigators. 3. Maintain a comprehensive, prospective, interactive sample database showing type (at diagnosis, at AML progression etc) and characteristics (DNA, RNA etc) of available MDS samples and of their subsequent disposition. 4. Facilitate intra- and extra- MDS P01 collaborations through sharing of blood and marrow resources. 5. Ascertain the incidence of NRAS, KRAS2, and PTPN11 mutations in patients at diagnosis and every 3 months thereafter. 6. Evaluate the possibility that mutations in PTPN11, RAS, and FLT3 can be used to quantify disease burden in MDS. 7. Measure biochemical endpoints of targeted therapeutics (in particular R115777) and correlate these pharmacodynamic data with responses to therapy given in Project 1.